Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309264 · ClinicalTrials.gov registry record · NA
Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans
A NA study of Auditory Diseases, Central, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT06309264: Recruiting NA study of Auditory Diseases, Central, sponsored by VA Office of Research and Development.
NCT06309264 is a NA study of Auditory Diseases, Central that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06309264, a NA study of Auditory Diseases, Central, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
Since 2000, at least 250,000 U.S. Service members have experienced a blast-related mild traumatic brain injury. A retrospective analysis of over 100,000 post-9/11 Veterans shows that blast injury more than doubles the risk of a diagnosed auditory problem. Many blast-exposed Veterans experience "functional hearing difficulties" (FHDs): problems in challenging listening environments despite clinically normal hearing as measured by the pure-tone audiogram. VA audiologists have begun using low-gain hearing aids to treat FHDs, but there are no concrete guidelines for this application given standard procedures rely on the pure-tone audiogram. This study proposes a data-driven approach called speech-based audiometry (SBA), which optimizes hearing aid gains from a patient's responses to speech stimuli in aided conditions. This trial will assess the behavioral (speech recognition in noise, subjective listening difficulty) and neurophysiological (functional neuroimaging during a speech recognition task) benefits of low-gain hearing aids programmed conventionally or with SBA among blast-exposed Veterans with FHDs.
Primary Outcome
Participants repeat back sentences embedded in four-talker babble, with each sentence presented at one of six signal-to-noise ratios decreasing from 33.5 dB to 8.5 dB in 5 dB steps. Each sentence is scored for number of correct keywords (out of five) and the total number correct over six sentences is subtracted by a normative value of 25.5 to obtain the "signal-to-noise ratio loss." The average signal-to-noise ratio loss across two sets of six sentences is obtained. The target sentences are time
Conditions Studied
Interventions
- DEVICE Phonak Lumina P90
Study Locations (3)
California
- VA Loma Linda Healthcare System, Loma Linda, CA - Loma Linda
- VA Greater Los Angeles Healthcare System, Sepulveda, CA - Sepulveda
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT06309264 shows while recruiting
NCT06309264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Auditory Diseases, Central appearing as the primary indexed condition, and to 1 intervention - of which Phonak Lumina P90 is the first listed.
NCT06309264 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06309264 about?
NCT06309264 is a clinical study titled "Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans". Since 2000, at least 250,000 U.S. Service members have experienced a blast-related mild traumatic brain injury. A retrospective analysis of over 100,000 post-9/11 Veterans shows that blast injury more than doubles the risk of a diagnosed auditory problem. Many blast-exposed Veterans experience "func...
What is the current status of trial NCT06309264?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-04-01. Estimated completion is 2028-03-31.
What conditions does trial NCT06309264 study?
This clinical trial studies the following conditions: Auditory Diseases, Central.
What interventions are being tested in trial NCT06309264?
The interventions under investigation include: Phonak Lumina P90 (DEVICE).
Who is sponsoring clinical trial NCT06309264?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309264 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06309264's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI